What's Happening?
California-based AI start-up Profluent has entered into a significant partnership with pharmaceutical giant Eli Lilly, valued at up to $2.25 billion. This collaboration focuses on advancing gene-editing therapies. Profluent, which launched in 2022, has developed
a technology platform capable of inserting entire genes into DNA, a process that surpasses the capabilities of current gene-editing techniques like CRISPR/Cas9. The partnership aims to utilize Profluent's AI models to design recombinase editors that can insert long stretches of DNA at precise genome locations. While specific details about the diseases targeted or the number of programs involved remain undisclosed, Lilly will have an exclusive license to further develop and commercialize selected recombinases. Profluent's approach could potentially address genetic diseases with high mutational heterogeneity by inserting complete functional genes, a long-sought goal in the gene-editing field.
Why It's Important?
This partnership marks a significant advancement in the field of gene-editing, potentially transforming the treatment of genetic diseases. By enabling the insertion of entire genes, Profluent's technology could address a wide range of mutations with a single therapeutic approach, rather than requiring separate solutions for each variant. This could lead to more efficient and comprehensive treatments for complex genetic disorders. For Eli Lilly, this collaboration enhances its capabilities in gene-editing technologies, complementing its existing efforts, such as the $700 million Lilly Institute for Genetic Medicine. The partnership also underscores the growing role of AI in biotechnology, as Profluent's use of large language models and programmable biology represents a cutting-edge approach to drug development.
What's Next?
As the partnership progresses, further details about the specific diseases targeted and the structure of the collaboration are expected to emerge. Eli Lilly's exclusive license to advance recombinases through various stages of development suggests a long-term commitment to bringing these therapies to market. The success of this partnership could encourage further investments in AI-driven gene-editing technologies, potentially leading to new collaborations and innovations in the field. Stakeholders in the pharmaceutical and biotech industries will likely monitor the outcomes closely, as successful development could set new standards for treating genetic diseases.
